



Vivacta Limited
 100 Guillat Avenue
 Kent Science Park
 Sittingbourne, Kent
 ME9 8GU United Kingdom

Tel +44 (0)1795 419400
Fax +44 (0)1795 419401
www.vivacta.com

COMPANY INFORMATION

The Company

Vivacta is a medical diagnostic business exploiting proprietary Piezofilm detection technology. Piezofilm detection allows rapid determination of highly sensitive binding assays including immunoassay and DNA / RNA. The initial development effort is focused on a "Point of Care" system comprising single use cartridges used in conjunction with a small format, portable reader.

Technology Differentiation

Immunoassays account for 42% of the value in lab diagnostics today, whereas in point of care (excluding glucose self testing) immunoassays only account for 25%. The reason for immunoassay's shortfall today in PoC is due in part to a lack of platform technologies capable of many of the higher sensitivity tests and where there is a need for quantitation with a wide dynamic range.

	Current technology: Photo-spectrometer	Vivacta Piezofilm: Initial Target Performance
Dynamic range	50-60X	1,000-10,000
Detection limit (pg/mL)	100	15
Test time	10-15 minutes	5-10 minutes

Another key technology differentiator relates to piezofilm's detection of analyte in whole blood without the need for wash steps or red-cell separation. This provides less complex cartridge design and provides a broad freedom to operate, avoiding the complex and litigious area of lateral flow and red cell separation IP.

Intellectual Property

Vivacta have a number of patents and applications providing broad protection relating to chemical detection and specifically binding assays using Piezofilm. Also there are multiple layers of further protection relating to key technologies that hold specific benefits relating to homogeneous and separation free assays.

Market Opportunities

The combination of wide dynamic range, ultra-high sensitivity and rapid test provide clear opportunities in the \$1.3 billion established "Heart Marker" sector as well as the emerging "acute diagnosis" markets for stroke, sepsis and acute kidney injury. The compelling need for rapid diagnosis in these acute care settings make the technology an ideal candidate.

Vivacta has demonstrated the system performance with the development of a test for the largest immunoassay application: the monitoring of thyroid function using TSH. This will be a first of its kind in simple potentially-CLIA Waived, PoC format. The test will allow patient screening for hypothyroidism, monitoring during drug titration, and instant checks for suspected thyrotoxic conditions through T4 overdose or hyperthyroidism. An additional application is for pre-contrast agent treatment before imaging procedures. The existing lab testing market for Thyroid Function is globally in excess of \$1 billion.

Exploitation

Vivacta plan to focus on product development, bringing new assays through pilot production stage in preparation for clinical trials. Relationships with partners are being sought, and it is anticipated the partner will market, manufacture and

Investors

Viking Technologies SA
 Spark Ventures
 HBM BioVentures
 AGF Private Equity

Board of Directors

Rolf Classon Chairman
 Jonathan Gee*
 Paddy Greenwood
 Gerry Moeller
 Gerard Vaillant
 Werner Schaefer
 Tim Carter CEO

*representing New Media Spark Directors Limited

Management Team

Tim Carter CEO
 Steve Ross R&D Dir.
 Sonja Johnston Quality Dir
 Stafford Moss Eng Mgr
 Nigel Newton Fin Dir

Lawyers: Taylor Wessing
 Auditors: Deloitte & Touche
 Bank: Nat West
 Patent Attorney: Elkington & Fife

Company number: 5397165

Investment

Series A, February 06 \$ 6m
 Series B, November 07 \$12m
 June 09 \$4.5m

Number of Employees

32 excluding the Board

Premises

12,000 sqft of purpose built laboratories, offices and cartridge pilot production.

handle regulatory clearance and ongoing compliance. Licences will be for therapeutic groups of markers. The technology has opportunities in the three primary Point of Care settings:

- Institutional acute care: ICU, ER
- Clinics: Endocrinology, Urology, Cardiology.
- Primary care, Physicians Office
- Self testing

Management

A management team with strong IVD experience, and a Board that includes a former Chairman and Presidents of IVD companies that include J&J, Roche and Bayer.

System Design for our TSH test

